Moderna announced that it plans to request an Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) and conditional approval from the European Medicines Agency (EMA) following the final final results from a late-stage study indicated its Covid-19 vaccine candidate is 94.1 % successful.
Moderna stated that its vaccine efficacy was 94.1 % and reached one hundred % in serious COVID-19 instances. It has also stated the vaccine is commonly properly tolerated and devoid of really serious security issues.
(Inputs from Agencies)